With semaglutide off-patent, a flood of low-cost generics is shifting the fight from molecules to brand names in India’s fast-growing weight-loss market
Novo Nordisk sues Dr. Reddy’s over Ozempic trademark
With semaglutide off-patent, a flood of low-cost generics is shifting the fight from molecules to brand names in India’s fast-growing weight-loss market
